Get the Stockscreener App
189.33
1.54%
-2.97
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $189.33, with a volume of 1.42M.
It is down -1.54% in the last 24 hours and up +1.91% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$192.30
Open:
$189.15
24h Volume:
1.42M
Relative Volume:
0.54
Market Cap:
$293.45B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
57.74
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
-7.55%
1M Performance:
+1.91%
6M Performance:
+127.32%
1Y Performance:
+172.23%
1-Day Range:
$187.56
$189.62
1-Week Range:
$187.56
$203.37
52-Week Range:
$66.16
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
189.22 | 298.23B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
882.60 | 819.79B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.82 | 555.22B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.02 | 355.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
NVS
Novartis Ag Adr
|
145.08 | 281.41B | 54.72B | 14.02B | 15.32B | 7.1855 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Big pharma in focus: What’s driving AstraZeneca and GSK right now - AJ Bell
Clinical Trial Software Research Report 2026: $2.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
GSK doubles down on oncology as AstraZeneca’s pipeline cranks up - Investors' Chronicle
Nordic Equities in North AmericaAstraZeneca declines 1.2 percent - marketscreener.com
Earnings Preview: AstraZeneca to Report Financial Results Pre-market on April 29 - Moomoo
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance Singapore
AstraZeneca Advances New Imaging Tool in Targeted Lung Cancer Trial - TipRanks
ASTRAZENECA : JP Morgan reiterates its Buy rating - marketscreener.com
AstraZeneca announces board change as Rene Haas to step down as director - Investing.com
AstraZeneca (NYSE: AZN) board member Rene Haas to step down - Stock Titan
Arm's Haas to leave AstraZeneca board amid new SoftBank role - marketscreener.com
IN BRIEF: Arm's Haas to leave AstraZeneca board amid new SoftBank role - London South East
AstraZeneca Announces Directorate Change: Rene Haas to Step Down - Devdiscourse
AstraZeneca Advances Kidney Care With Ultomiris Breakthrough - Kalkine Media
AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data - Clinical Trials Arena
AstraZeneca Advances Kidney Care with Ultomiris Trial Success - Kalkine Media
AstraZeneca (AZN) Seeks Accelerated Approval for Ultomiris in Ig - GuruFocus
T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage - Yahoo Finance
AstraZeneca slides Tuesday, underperforms market - MarketWatch
AstraZeneca's Ultomiris Meets Goal in Rare Kidney Disease Study - Yahoo Finance
AstraZeneca’s Ultomiris Hits Interim Phase III Endpoint In IgAN, Eyes Accelerated Filings - Citeline News & Insights
Seller pressure near £14,350–£14,800 weighs on AstraZeneca stock price - Traders Union
Germany risks missing out on new drugs, AstraZeneca CEO tells paper - Reuters
AstraZeneca's tozorakimab treble puts $5bn sales ceiling in sight, says Citi - Proactive Investors
AstraZeneca (AZN) Reports Positive Interim Results from I CAN Tr - GuruFocus
AstraZeneca Drug Advances Spark Strong Market Attention - Kalkine Media
AstraZeneca’s COPD drug gains third Phase III win - Clinical Trials Arena
AstraZeneca reports Ultomiris meets primary endpoint in IgAN Phase III trial - Investing.com
Ultomiris IgAN Phase III interim success boosts AstraZeneca (AZN) rare kidney portfolio - Stock Titan
AstraZeneca says Ultomiris meets primary endpoint in phase III trial - marketscreener.com
ASTRAZENECA : Gets a Buy rating from JP Morgan - marketscreener.com
Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - GlobeNewswire Inc.
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.
Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - GlobeNewswire Inc.
AstraZeneca receives positive high level results from Phase III I CAN trial - Sharecast.com
AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trial - Proactive financial news
AstraZeneca reports Ultomiris meets primary endpoint in phase III trial for IgAN at week 34 - marketscreener.com
AstraZeneca's Breakthrough in IgAN Treatment: Ultomiris Triumphs in Phase III Trials - Devdiscourse
AstraZeneca PLC stock (US6549022043): Is its oncology pipeline strong enough to unlock new upside? - AD HOC NEWS
Lobbying Update: $2,280,000 of ASTRAZENECA PHARMACEUTICALS LP lobbying was just disclosed - Quiver Quantitative
AstraZeneca PLC stock (US6549022043): Is its oncology dominance strong enough to drive sustained ups - AD HOC NEWS
AstraZeneca stock slips as weak momentum limits further upside - Traders Union
AstraZeneca (AZN) Achieves Success in Late-Stage COPD Trial for Tozorakimab - GuruFocus
AstraZeneca's tozorakimab delivers reduction in chronic lung disease flare‑ups - Reuters
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca Builds COPD Case For Tozorakimab With Third Positive Phase III Trial - Citeline News & Insights
Generic Injectables Market Major PlayersAstrazeneca, Baxter - openPR.com
AstraZeneca (AZN) Stock: Tozorakimab Achieves Phase III COPD Success in MIRANDA Study - Blockonomi
AstraZeneca (AZN) Stock: COPD Drug Tozorakimab Hits Phase III Trial Goals - CoinCentral
AstraZeneca (AZN) scores third positive Phase III COPD result for tozorakimab - Stock Titan
COPD patients saw fewer flare-ups in AstraZeneca's third Phase III trial - Stock Titan
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
5.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):